Lorcaserin Clears Its Final Hurdle to Launch at DEA
May 8, 2013 — Almost a year after FDA approved lorcaserin (Belviq®) for introduction in the U.S. and recommended that DEA label it as a class IV controlled substance, DEA has finally cleared the way by concurring with FDA’s recommendation. Class IV is the second least restrictive class for drugs with abuse potential and is the same class assigned […]
